Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update.

Cytomegalovirus Expert Infection Prevention Recommendations SOT Transplantation

Journal

Transplantation reviews (Orlando, Fla.)
ISSN: 1557-9816
Titre abrégé: Transplant Rev (Orlando)
Pays: United States
ID NLM: 8804364

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 08 07 2024
revised: 02 08 2024
accepted: 03 08 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 21 8 2024
Statut: aheadofprint

Résumé

Cytomegalovirus (CMV) infection remains a significant challenge in solid organ transplantation (SOT). The last international consensus guidelines on the management of CMV in SOT were published in 2018, highlighting the need for revision to incorporate recent advances, notably in cell-mediated immunity monitoring, which could alter the current standard of care. A working group including members from the Group for the Study of Infection in Transplantation and the Immunocompromised Host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Transplantation (SET), developed consensus-based recommendations for managing CMV infection in SOT recipients. Recommendations were classified based on evidence strength and quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. The final recommendations were endorsed through a consensus meeting and approved by the expert panel.

Identifiants

pubmed: 39168020
pii: S0955-470X(24)00058-2
doi: 10.1016/j.trre.2024.100875
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100875

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Julian Torre-Cisneros reports administrative support, article publishing charges, travel, and writing assistance were provided by Spanish Society of Infectious Diseases and Clinical Microbiology. Julian Torre-Cisneros reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: consulting or advisory and speaking and lecture fees. Julian Torre-Cisneros reports a relationship with Takeda Pharmaceutical Company Limited that includes: consulting or advisory. Julian Torre-Cisneros reports a relationship with Biotest AG that includes: consulting or advisory and speaking and lecture fees. Julian Torre-Cisneros reports a relationship with QIAGEN GmbH that includes: consulting or advisory, funding grants, and speaking and lecture fees. Jose Maria Aguado reports a relationship with Mundipharma International Limited that includes: consulting or advisory and speaking and lecture fees. Jose Maria Aguado reports a relationship with Pfizer that includes: consulting or advisory and speaking and lecture fees. Jose Maria Aguado reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: consulting or advisory and speaking and lecture fees. Jose Maria Aguado reports a relationship with Takeda Pharmaceutical Company Limited that includes: consulting or advisory and speaking and lecture fees. Sara Cantisan reports a relationship with QIAGEN GmbH that includes: funding grants and speaking and lecture fees. Juan Jose Caston reports a relationship with Pfizer Inc. that includes: funding grants and speaking and lecture fees. Juan Jose Caston reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: speaking and lecture fees. Juan Jose Caston reports a relationship with A Menarini International Pharmaceutics that includes: speaking and lecture fees. Juan Jose Caston reports a relationship with Novartis Pharmaceuticals Corporation that includes: speaking and lecture fees. Juan Jose Caston reports a relationship with QIAGEN GmbH that includes: funding grants and speaking and lecture fees. Carme Facundo reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: consulting or advisory. Mirian Fernandez-Alonso reports a relationship with Roche Diagnostics Corporation that includes: travel reimbursement. Mirian Fernandez-Alonso reports a relationship with Werfen that includes: travel reimbursement. Mirian Fernandez-Alonso reports a relationship with QIAGEN GmbH that includes: non-financial support. Mario Fernandez-Ruiz reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: consulting or advisory. Mario Fernandez-Ruiz reports a relationship with Biotech that includes: consulting or advisory. Sabina Herrera reports a relationship with Pfizer Inc. that includes: speaking and lecture fees and travel reimbursement. Sabina Herrera reports a relationship with Shionogi Inc. that includes: speaking and lecture fees. Sabina Herrera reports a relationship with Shire that includes: travel reimbursement. Sabina Herrera reports a relationship with A Menarini International Pharmaceutics that includes: travel reimbursement. Oscar Len reports a relationship with Pfizer that includes: funding grants and speaking and lecture fees. Oscar Len reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: funding grants and speaking and lecture fees. Oscar Len reports a relationship with Astellas Pharma Inc. that includes: speaking and lecture fees. Oscar Len reports a relationship with Novartis Pharmaceuticals Corporation that includes: speaking and lecture fees. Ibai Los-Arcos reports a relationship with Pfizer Inc. that includes: speaking and lecture fees and travel reimbursement. Ibai Los-Arcos reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: speaking and lecture fees and travel reimbursement. Ibai Los-Arcos reports a relationship with Gilead Sciences Inc. that includes: travel reimbursement. Ibai Los-Arcos reports a relationship with A Menarini International Pharmaceutics that includes: travel reimbursement. David Navarro reports a relationship with Roche Diagnostics Corporation that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with Abbott that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with bioMérieux SA that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with Beckton Dickinson that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with Gilead Sciences Inc. that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with Takeda Pharmaceutical Company Limited that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: consulting or advisory and speaking and lecture fees. David Navarro reports a relationship with Pfizer Inc. that includes: consulting or advisory and speaking and lecture fees. Maricela Valerio reports a relationship with Pfizer Inc. that includes: speaking and lecture fees and travel reimbursement. Maricela Valerio reports a relationship with Merck Sharp & Dohme UK Ltd. that includes: speaking and lecture fees and travel reimbursement. Maricela Valerio reports a relationship with Shionogi and Co Ltd. that includes: speaking and lecture fees and travel reimbursement. Maricela Valerio reports a relationship with GSK that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Elisa Ruiz-Arabi (E)

Service of Infectious Diseases, Reina Sofia University Hospital, Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain.

Julian Torre-Cisneros (J)

Service of Infectious Diseases, Reina Sofia University Hospital. Maimonides Institute for Biomedical Research (IMIBIC), University of Cordoba, Córdoba, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: julian.torre@sspa.juntadeandalucia.es.

Victoria Aguilera (V)

Hepatology and Liver Transplantation Unit, Hospital Universitario La Fe-IIS La Fe Valencia, CiberEHD and University of Valencia, Spain.

Rodrigo Alonso (R)

Lung Transplant Unit, Pneumology Service, Instituto de Investigación Hospital 12 de Octubre (imas12), University Hospital 12 de Octubre, Madrid, Spain.

Marina Berenguer (M)

Hepatology and Liver Transplantation Unit, Hospital Universitario La Fe-IIS La Fe Valencia, CiberEHD and University of Valencia, Spain.

Oriol Bestard (O)

Department of Nephrology and Kidney Transplantation, Vall d'Hebron University Hospital-VHIR, Barcelona, Spain.

Marta Bodro (M)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Hospital Clinic-IDIBAPS, University of Barcelona, Spain.

Sara Cantisán (S)

Service of Infectious Diseases, Reina Sofia University Hospital. Maimonides Institute for Biomedical Research (IMIBIC), University of Cordoba, Córdoba, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Jordi Carratalà (J)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Bellvitge University Hospital-IDIBELL, University of Barcelona, Spain.

Juan José Castón (JJ)

Service of Infectious Diseases, Reina Sofia University Hospital. Maimonides Institute for Biomedical Research (IMIBIC), University of Cordoba, Córdoba, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

Elisa Cordero (E)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital, Junta de Andalucía, CSIC, Universidad de Sevilla, Sevilla, Spain; Departament of Medicine, Faculty of Medicine, Universidad de Sevilla, Spain.

Carme Facundo (C)

Department of Nephrology, Fundacio Puigvert, Institut de Recerca Sant Pau (IR Sant Pau), RICORS 2024 (Kidney Disease), Barcelona, Spain.

María Carmen Fariñas (MC)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Hospital Universitario Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, Santander, Spain.

Mirian Fernández-Alonso (M)

Microbiology Service, Clínica Universidad de Navarra, IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Mario Fernández-Ruiz (M)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain.

Jesús Fortún (J)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Service of Infectious Diseases, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain.

Maria Dolores García-Cosío (MD)

Department of Cardiology, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), CIBERCV, Madrid, Spain.

Sabina Herrera (S)

Department of Infectious Diseases, Hospital Clinic-IDIBAPS, University of Barcelona, Spain.

David Iturbe-Fernández (D)

Department of Pneumology, University Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain.

Oscar Len (O)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.

Francisco López-Medrano (F)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain.

María Ovidia López-Oliva (MO)

Department of Nephrology, University Hospital La Paz, Madrid, Spain.

Ibai Los-Arcos (I)

Department of Infectious Diseases, Vall d'Hebron for Solid Organ Transplantation Research Group, Vall d'Hebron University Hospital, Barcelona, Spain.

María Ángeles Marcos (MÁ)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Department of Clinical Microbiology, Hospital Clinic, University of Barcelona, ISGlobal Barcelona Institute for Global Health, Barcelona, Spain.

Pilar Martín-Dávila (P)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Service of Infectious Diseases, Ramón y Cajal University Hospital, IRYCIS, Madrid, Spain.

Víctor Monforte (V)

Lung Transplant Program, Department of Pulmonology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.

Patricia Muñoz (P)

CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitario Gregorio Marañon, Departamento de Medicina, Universidad Complutense, Madrid, Spain.

David Navarro (D)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. Department of Microbiology School of Medicine, University of Valencia, Spain.

Aurora Páez-Vega (A)

Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain.

Ana Belén Pérez (AB)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Microbiology Unit, Hospital Universitario Reina Sofía-Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain.

Natalia Redondo (N)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain.

Regino Rodríguez Álvarez (RR)

Unit of Infectious Diseases, Hospital Universitario Cruces, Bilbao, Spain.

Alberto Rodríguez-Benot (A)

Department of Nephrology, Reina Sofía University Hospital, Cordoba, Spain.

Isabel Rodríguez-Goncer (I)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain.

Rafael San-Juan (R)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain.

Javier Sánchez-Céspedes (J)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, Microbiology and Parasitology, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocío University Hospital, Junta de Andalucía, CSIC, Universidad de Sevilla, Sevilla, Spain.

Maricela Valerio (M)

CIBER Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitario Gregorio Marañon, Departamento de Medicina, Universidad Complutense, Madrid, Spain.

José Manuel Vaquero (JM)

Unit of Pneumology, Thoracic Surgery, and Lung Transplant, Reina Sofía University Hospital, Cordoba, Spain.

Diego Viasus (D)

Division of Health Sciences, Faculty of Medicine, Universidad del Norte, Hospital Universidad del Norte, Barranquilla, Colombia.

Elisa Vidal (E)

Service of Infectious Diseases, Reina Sofia University Hospital. Maimonides Institute for Biomedical Research (IMIBIC), University of Cordoba, Córdoba, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.

José María Aguado (JM)

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (i+12), School of Medicine, Universidad Complutense, Madrid, Spain. Electronic address: jaguadog1@gmail.com.

Classifications MeSH